GSK, researchers still probing Pandemrix links to narcolepsy; CHMP wants more justification for Arena's Belviq;

@FiercePharma: ADHD diagnoses up 24% over past 10 years; study author cites "better diagnosis" and possible "upward trend." More | Follow @FiercePharma

 @AlisonBFierce: Vanderbilt University has emerged as a leading institution for central nervous system drug research and discovery. Editor's Corner | Follow @AlisonBFierce

@EricPFierce: Plant problems stymie Impax NDA for Parkinson drug, FDA says. Article | Follow @EricPFierce

> GlaxoSmithKline ($GSK) and independent researchers continue to probe a possible link between the pandemic flu shot Pandemrix and hundreds of cases of narcolepsy. Report

> European regulators asked Arena Pharmaceuticals ($ARNA) to "further justify" the safety and efficacy of its weight-loss drug Belviq, which awaits a recommendation from the Committee for Medicinal Products for Human Use. Report

> GlaxoSmithKline is cutting the calories and sugar in its energy and nutrition drinks Lucozade and Ribena, as part of a government plan to fight obesity. Report

> Italy's Recordati wrapped up its $100 million buyout of a portfolio of Lundbeck's U.S. product rights, including Panhematin and NeoProfen. Release | Report

> The number of children diagnosed with Attention Deficit Hyperactivity Disorder rose by 24% over the past decade, partly because of improved diagnosis, a JAMA Pediatrics study found. Report

Medical Device News

 @FierceMedDev: J&J device revenue jumped 6.4% in 2012 thanks to Synthes buy. Report | Follow @FierceMedDev

 @DamianFierce: If $LIFE is indeed for sale, that's not stopping it from pursuing more M&A of its own. More | Follow @DamianFierce

> Welch Allyn snags FDA clearance for iPhone-friendly eye scope. Article

> Invacare closes $150M unit sale as it reels from FDA fallout. Story

Biotech News

 @FierceBiotech: Novo Nordisk nabs European OK on blockbuster diabetes drug hopeful. News | Follow @FierceBiotech

@JohnCFierce: As CRL letters go, Impax would seem to have a low hurdle ahead on its sustained release Parkinson's drug. More | Follow @JohnCFierce

@RyanMFierce: Software outfit tackles multi-billion dollar bugaboo in clinical trials. Article | Follow @RyanMFierce

> New $80M venture fund to back startups entering 'valley of death.' Story

> Biotech vet Astley-Sparke takes U.S. lead for pioneering gene therapy player. Article

Biotech IT News

> New chief named for Perceptive Informatics. Story

> U.K. regulator finds social media groove…finally. Item

> Software outfit tackles multi-billion dollar bugaboo in clinical trials. Article

> Elsevier rumored as potential buyer of open science startup. News

CRO News

> Is GlaxoSmithKline stretching its contractors too thin? Story

> Covance teams with U.K.'s NHS Trust on Phase I trials. Report

> Clinipace rejiggers eClinical platform. Article

> Quintiles lands pathology accreditation for Indian lab. News

Pharma Manufacturing News

> BASF lands Pronova making it a top omega-3 maker. Report

> Pfizer to develop laser cleaning verification system. Item

> Cargo theft down in year of key arrests. News

> Plant problems stymie Impax NDA, FDA says. Article

Biotech Research News

> Calcium receptor could stop sleeping sickness in its tracks. Item

> Oral breast cancer vaccine could prevent recurrence. Article

> A great leap forward: Microdystrophin gene therapy success in dogs. Report

> Glowing mice could blaze way for detecting, tracking cancer growth. News

And Finally... Doctors need better training in talking about new drugs to their patients, a study found. Report